Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans

Pharmacogenomics

Volumn 13, Issue 16, 2012, Pages 1925-1935

  Bress, Adam ^a   Patel, Shitalben R ^a   Perera, Minoli A ^b   Campbell, Richard T ^a   Kittles, Rick A ^a   Cavallari, Larisa H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

CYP2C9; CYP4F2; genotype; NQO1; VKORC1; warfarin

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ADULT; AFRICAN AMERICAN; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; CYP4F2 GENE; CYTOCHROME P450 2C9 GENE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; HISPANIC; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUTATOR GENE; NQO1 GENE; PHARMACOGENETICS; RACE DIFFERENCE; VKORC1 GENE;

ADULT; AFRICAN AMERICANS; AGED; ANTICOAGULANTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); WARFARIN;

EID: 84870856239     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.12.164     Document Type: Article

References (46)

1. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N. Engl. J. Med. 365(21), 2002-2012 (2011).
2. Wadelius M, Chen LY, Lindh JD et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113(4), 784-792 (2009).
3. Klein TE, Altman RB, Eriksson N et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360(8), 753-764 (2009).
4. Gage BF, Eby C, Johnson JA et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84(3), 326-331 (2008).
5. Gong X, Gutala R, Jaiswal AK. Quinone oxidoreductases and vitamin K metabolism. Vitam. Horm. 78, 85-101 (2008).
6. Traver RD, Siegel D, Beall HD et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br. J. Cancer 75(1), 69-75 (1997).
7. Kelsey KT, Ross D, Traver RD et al. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 76(7), 852-854 (1997).
8. Siegel D, McGuinness SM, Winski SL, Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P) H:quinone oxidoreductase 1. Pharmacogenetics 9(1), 113-121 (1999).
9. Covarrubias VG, Lakhman SS, Forrest A, Relling MV, Blanco JG. Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol. Lett. 164(3), 249-258 (2006).
10. De Haan LH, Boerboom AM, Rietjens IM et al. A physiological threshold for protection against menadione toxicity by human NAD(P)H: quinone oxidoreductase (NQO1) in Chinese hamster ovary (CHO) cells. Biochem. Pharmacol. 64(11), 1597-1603 (2002).
11. de Visser MC, Roshani S, Rutten JW et al. Haplotypes of VKORC1, NQO1 and GGCX, their effect on activity levels of vitamin K-dependent coagulation factors, and the risk of venous thrombosis. Thromb. Haemost. 106(3), 563-565 (2011).
12. Shyu HY, Fong CS, Fu YP et al. Genotype polymorphisms of GGCX, NQO1, and VKORC1 genes associated with risk susceptibility in patients with large-artery atherosclerotic stroke. Clin. Chim. Acta 411(11-12), 840-845 (2010).
13. Ramirez AH, Shi Y, Schildcrout JS et al. Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics 13(4), 407-418 (2012).
14. Caldwell MD, Awad T, Johnson JA et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111(8), 4106-4112 (2008).
15. Stec DE, Roman RJ, Flasch A, Rieder MJ. Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 30(1), 74-81 (2007).
16. Singh O, Sandanaraj E, Subramanian K, Lee LH, Chowbay B. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. Drug Metab. Pharmacokinet. 26(2), 130-136 (2011).
17. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75(6), 1337-1346 (2009).
18. Borgiani P, Ciccacci C, Forte V et al. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10(2), 261-266 (2009).
19. Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH. Factors influencing warfarin dose requirements in African-Americans. Pharmacogenomics 8(11), 1535-1544 (2007).
20. Cavallari LH, Langaee TY, Momary KM et al. Genetic and clinical predictors of warfarin dose requirements in African Americans. Clin. Pharmacol. Ther. 87(4), 459-464 (2010).
21. Cavallari LH, Momary KM, Patel SR, Shapiro NL, Nutescu E, Viana MA. Pharmacogenomics of warfarin dose requirements in Hispanics. Blood Cells Mol. Dis 46(2), 147-150 (2011).
22. Andrisin TE, Humma LM, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22(8), 954-960 (2002).
23. Aquilante CL, Langaee TY, Lopez LM et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79(4), 291-302 (2006).
24. Hruska MW, Frye RF, Langaee TY. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin. Chem. 50(12), 2392-2395 (2004).
25. Perera MA, Gamazon E, Cavallari LH et al. The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin. Pharmacol. Ther. 89(3), 408-415 (2011).
26. Giri VN, Egleston B, Ruth K et al. Race, genetic west African ancestry, and prostate cancer prediction by prostate-specific antigen in prospectively screened high-risk men. Cancer Prev. Res. (Phila.) 2(3), 244-250 (2009).
27. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF. A genomewide single-nucleotide-polymorphism panel with high ancestry information for African-American admixture mapping. Am. J. Hum. Genet. 79(4), 640-649 (2006).
28. Limdi NA, Wadelius M, Cavallari L et al. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3. racial groups. Blood 115(18), 3827-3834 (2010).
29. Shahin MH, Khalifa SI, Gong Y et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenetics Genomics 21(3), 130-135 (2011).
30. Morin S, Bodin L, Loriot MA et al. Pharmacogenetics of acenocoumarol pharmacodynamics. Clin. Pharmacol. Ther. 75(5), 403-414 (2004).
31. Roger VL, Go AS, Lloyd-Jones DM et al. Executive summary: heart disease and stroke statistics-2012. update: a report from the American Heart Association. Circulation 125(1), 188-197 (2012).
32. Shen AY, Contreras R, Sobnosky S et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults-a cross-sectional study. J. Natl Med. Assoc. 102(10), 906-913 (2010).
33. Valentin II, Vazquez J, Rivera-Miranda G et al. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes. Ann. Pharmacother. 46(2), 208-218 (2012).
34. Palacio L, Falla D, Tobon I et al. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate. Clin. Appl. Thromb. Hemost. 16(1), 83-90 (2010).
35. Ruano G, Duconge J, Windemuth A et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics 10(4), 565-577 (2009).
36. Martinez-Cortes G, Salazar-Flores J, Gabriela Fernandez-Rodriguez L et al. Admixture and population structure in Mexican-Mestizos based on paternal lineages. J. Hum. Genet. 57(9), 568-574 (2012).
37. Ernster L, Lind C, Rase B. A study of the DT-diaphorase activity of warfarin-resistant rats. Eur. J. Biochem. 25(1), 198-206 (1972).
38. Wadelius M, Chen LY, Eriksson N et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121(1), 23-34 (2007).
39. Nassir R, Kosoy R, Tian C et al. An ancestry informative marker set for determining continental origin: validation and extension using human genome diversity panels. BMC Genet. 10, 39. (2009).
40. Gonzalez Burchard E, Borrell LN, Choudhry S et al. Latino populations: a unique opportunity for the study of race, genetics, and social environment in epidemiological research. Am. J. Public Health 95(12), 2161-2168 (2005).
41. Cooper GM, Johnson JA, Langaee TY et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112(4), 1022-1027 (2008).
42. Takeuchi F, McGinnis R, Bourgeois S et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5(3), e1000433 (2009).
43. Cha PC, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum. Mol. Genet. 19(23), 4735-4744 (2011).
44. Perera MA, Limdi NA, Cavallari L et al. Novel SNPs associated with warfarin dose in a large multicenter cohort of African-Americans: genome wide association study and replication results. Circulation 124(Suppl. 1), Abstract 15518. (2011).
45. Geisen C, Watzka M, Sittinger K et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb. Haemost. 94(4), 773-779 (2005).
46. Pan SS, Forrest GL, Akman SA, Hu LT. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116. cells. Cancer Res. 55(2), 330-335 (1995).